Despite the global economic slowdown, biologics managed single-digit growth in 2008, driven mainly by continued high growth in sales of antibodies and insulins. Novel biologics in development look promising, but crowding, pricing and reimbursement are emerging as longer-term concerns.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Aggarwal, S. Nat. Biotechnol. 26, 1227–1233 (2008).
Anonymous. IMS Health Reports U.S. Prescription Sales Grew 1.3 Percent in 2008 to $291 Billion. IMS, Norwalk, CT, USA, March 19, 2009. http://www.imshealth.com/portal/site/imshealth/ menuitem.a46c6d4df3db4b3d88f611019418c22a/ ?vgnextoid=078ce5b87da10210VgnVCM100000ed152ca2RCRD& vgnextchannel=41a67900b55a5110VgnVCM10000071812ca2 RCRD&vgnextfmt=default
Aggarwal, S. Nat. Biotechnol. 25, 1097–1104 (2007).
Spaide, R.F. et al. Retina 26, 383–390 (2006).
Kenneth, R.C. et al. Blood 113, 4834–4840 (2009).
Leavitt, M.O. A Design for a Bundled End Stage Renal Disease Prospective Payment System. Report to Congress, 2008.http://www.cms.hhs.gov/ESRDGeneralInformation/downloads/ ESRDReportToCongress.pdf
United States Government Accountability Office Report to Congressional Committees. Bundling Medicare's Payment for Drugs with Payment for All ESRD Services Would Promote Efficiency and Clinical Flexibility (US GAO, Washington, DC, USA, 2006) http://www.gao.gov/products/GAO-07-77
Jonasson, J.M. et al. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 52, 1745–1754 (2009).
Rosenstock, J. et al. Diabetologia 52, 1971–1973 (2009).
Cohen, J. et al. Oral fingolimod (FTY720) versus interferon β-1a in relapsing-remitting multiple sclerosis: results from a Phase III study (TRANSFORMS). Slide deck associated with oral presentation at the American Academy of Neurology Annual Meeting 2009, Seattle, April 25–May 2, 2009.
Babbit, B., Nick, C. & Aggarwal, S. Product Development Strategies for Follow-on Biologics Part II, Windhover, Norwalk, CT, April 23, 2009. http://www.windhover.com/ezine/html/ac0409-lp.htm
About this article
Plasmon-Enhanced Pan-Microbial Pathogen Inactivation in the Cavitation Regime: Selectivity Without Targeting
ACS Applied Nano Materials (2019)
Biochemical and metabolic engineering approaches to enhance production of therapeutic proteins in animal cell cultures
Biochemical Engineering Journal (2018)
A recombinant avian antibody against VP2 of infectious bursal disease virus protects chicken from viral infection
Research in Veterinary Science (2017)